Abstract: Solid dosage forms containing nanoparticles are prepared where sugar esters serve as nanoparticle stabilizers that prevent agglomeration of nanoparticles during preparation of the solid dosage form and allow for restoration of the original nanoparticle size of the nanoparticles upon redispersion of the solid dosage form in aqueous media.

Abstract: Solid dosage forms containing nanoparticles are prepared where sugar esters serve as nanoparticle stabilizers that prevent agglomeration of nanoparticles during preparation of the solid dosage form and allow for restoration of the original nanoparticle size of the nanoparticles upon redispersion of the solid dosage form in aqueous media.

Abstract: Sustained release pharmaceutical compositions that contain imatinib or a pharmaceutically acceptable salt thereof. The pharmaceutical compositions further contain a release retardant, for example a water soluble, a water swellable and/or a water insoluble polymer. The present invention also features a particularly useful process of making such sustained release pharmaceutical compositions by using an extruder.

Abstract: A process for preparing solid dosage forms that contain poorly compressible therapeutic compound. The process, for example, provides for the inventive use of an extruder, especially a twin screw extruder, to melt granulate a therapeutic compound(s) with a granulation excipient.

Abstract: A process for manufacturing solid oral dosage forms in an equipment train that comprises multiple pieces of apparatus designed for unit operations, such as blending, extruding, cooling, milling and finishing. The equipment in the equipment train allow for the transfer of raw materials and intermediate-processed materials from one apparatus to the next using transfer means, for example, gravity, vacuum, belts, and the like.

Abstract: A process for using a heated roller compactor to prepare melt granulated composition of a therapeutic compound, especially a poorly compressible and/or moisture sensitive therapeutic compound, with a granulation excipient.

Abstract: Sustained release pharmaceutical compositions that contain imatinib or a pharmaceutically acceptable salt thereof. The pharmaceutical compositions further contain a release retardant, for example a water soluble, a water swellable and/or a water insoluble polymer. The present invention also features a particularly useful process of making such sustained release pharmaceutical compositions by using an extruder.

Abstract: An ifetroban composition is provided which has good dissolution properties even on aging, when dispersed in water has a pH of at least 7 and includes a salt of ifetroban, one or more basifying agents, such as magnesium oxide or calcium carbonate, and where in tablet form includes one or more fillers such as mannitol and/or microcrystalline cellulose, one or more disintegrating agents such as crospovidone, one or more lubricants such as magnesium stearate, optionally one or more glidants such as colloidal silicon dioxide, one or more binders such as pregelatinized starch (dry binder) or polyvinyl-pyrrolidone (wet binder) and optionally a film coating containing a film former such as hydroxypropyl cellulose and a plasticizer such as 1,2,3-propanetriol triacetate.

Abstract: A sustained release captopril formulation is provided which is in the form of a capsule containing captopril in a semi-solid matrix of at least one fatty acid glyceride and/or polyethylene glycol ester. A method of preparing such a formulation is also provided.

Abstract: A steroid lotion formulation which has enhanced physical and chemical stability is formed of (11.beta.,17.alpha.)-17-(ethylthio)-9.alpha.-fluoro-11.beta.-hydroxy-17-(m ethylthio)androsta-1,4-diene-3-one (tipredane), and a vehicle containing as major ingredients polyethylene glycol, propylene glycol and water together with a potassium citrate buffer or tromethamine buffer, and sodium metabisulfite and butylated hydroxytoluene as antioxidants.